Re: validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion

We thank Dr Cucchetti and Colleagues for their letter on our recently published proposal of prognostic stratification for patients with hepatocellular carcinoma (HCC) and tumoral portal vein thrombosis (PVTT) undergoing Yttrium-90 trans-arterial radioembolization (TARE)[1]. By combining three easily available baseline parameters (bilirubin levels, PVTT extension and tumor burden) we found that it is possible to markedly stratify prognosis of patients undergoing TARE, and thus to refine treatment allocation avoiding futile treatments.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research